Safety, Tolerance and Pharmacokinetics of THR-1442 in Chinese Healthy Subjects
Primary Purpose
T2DM (Type 2 Diabetes Mellitus)
Status
Recruiting
Phase
Phase 1
Locations
China
Study Type
Interventional
Intervention
THR-1442 20mg Single dose
THR-1442 20mg Multiple dose group
Sponsored by
About this trial
This is an interventional treatment trial for T2DM (Type 2 Diabetes Mellitus)
Eligibility Criteria
Inclusion Criteria:
- Be able to understand and be willing to sign informed consent and voluntarily participate in the study;
- Chinese women or men aged 18-45 (including 18 and 45) at the time of screening;
- Men or women who agree to effective contraception from the screening period until 30 days after the last dose in the trial; Agree to take at least one effective contraceptive measure;
- During screening and baseline, male weight ≥ 50.0kg, female weight ≥ 45.0kg, body mass index (BMI) in the range of 19 ~ 25.0kg/m2 (including 19 and 25.0kg/m2), [BMI = weight (kg) / height 2 (M2)];
Exclusion Criteria:
- According to the judgment of the site investigators, including clinical significant medical history in CNS, CV system, respiratory system, blood / hematopoietic system, gastrointestinal system, liver / kidney system,etc;
- Subjects with specific allergic history or allergic constitution such as drugs, food and pollen, or allergic to SGLT2 inhibitors or similar drugs;
- Alcoholics (drinking 14 units per week, each unit equivalent to 360mL beer or 150mL wine or 45mL alcohol of 40% alcohol), drug or drug dependence subjects; Smokers (smoking > 5 cigarettes per day or the same amount of other tobacco products);
- Subjects with a history of bladder dysfunction, such as urinary incontinence, frequent urination or nocturia;
- Blood donation within 3 months before screening, including component blood or massive blood loss (≥ 200ml), receiving blood transfusion or using blood products;
- Subjects who used prescription drugs, traditional Chinese medicine, over-the-counter drugs (OTC), vitamins, dietary supplements or supplements (e.g. ginseng) within 4 weeks before the first administration;
- From 7 days before the first dose to the whole study period, subjects who are unwilling or unable to guarantee to forbid by the following: no smoking, no alcohol, no caffeine containing products (including chocolate, tea, coffee, cola, etc.) and avoid strenuous exercise;
- Those who are unwilling or unable to guarantee to forbid pitaya, grapefruit, mango, carambola, fruit juice and spicy food containing the above fruits from 7 days before taking the medicine and the whole test period;
- The subject was unable to swallow the study drug or had gastrointestinal diseases leading to absorption disorders;
- Subjects who had participated in any drug or medical device clinical trial within 3 months before screening;
Sites / Locations
- Hangzhou First People's hospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Experimental
Arm Label
THR-1442 20mg Single dose group
THR-1442 20mg Multiple dose group
Arm Description
THR-1442 20mg Single dose group: subject will be administrated 1 dose of 20mg THR-1442 on day1, the follow up till day 7.
THR-1442 20mg Multiple dose group: subject will be administrated THR-1442 20mg QD on Day1-Day7, the follow up till day 14.
Outcomes
Primary Outcome Measures
Collect and evaluate TEAEs (including clinical AEs and Lab AEs) of THR-1442 in healthy subjects during study
Collect data(TEAEs including clinical AEs and lab AEs) on Day7 and Day14 to evaluate THR1442 safety and tolerability
Secondary Outcome Measures
Select and evaluate pharmacokinetic characteristics(AUC) of THR-1442 in healthy subjects during the study
Collect blood samples on Single dose part and multiple dose part to evaluate THR1442 PK parameters (AUC)
Select and evaluate pharmacokinetic characteristics(Cmax) of THR-1442 in healthy subjects during the study
Collect blood samples on Single dose part and multiple dose part to evaluate THR1442 PK parameters (Cmax)
Full Information
NCT ID
NCT05369078
First Posted
December 6, 2021
Last Updated
May 5, 2022
Sponsor
Newsoara Biopharma Co., Ltd.
1. Study Identification
Unique Protocol Identification Number
NCT05369078
Brief Title
Safety, Tolerance and Pharmacokinetics of THR-1442 in Chinese Healthy Subjects
Official Title
Phase I Clinical Study to Evaluate the Safety, Tolerance and Pharmacokinetics of THR-1442 in Chinese Healthy Subjects
Study Type
Interventional
2. Study Status
Record Verification Date
December 2021
Overall Recruitment Status
Recruiting
Study Start Date
December 1, 2021 (Actual)
Primary Completion Date
May 31, 2022 (Anticipated)
Study Completion Date
May 31, 2022 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Newsoara Biopharma Co., Ltd.
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of this study was to investigate Safety, tolerability and pharmacokinetics in Chinese healthy subjects.
Detailed Description
This was a single center, Phase 1, open-label SAD and MAD study designed to assess safety, tolerability and PK of orally administered THR-1442 tablets in Chinese healthy adults.
Subjects were enrolled to receive 20mg THR-1442 tablet in Single dose group (20mg*1 day) and multiple dose group(20mg*7days).
Blood samples for THR-1442 plasma concentrations were collected 0h till to 48hours.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
T2DM (Type 2 Diabetes Mellitus)
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Parallel Assignment
Model Description
Study includes 2 parts: Single does part and multiple dose part. Single does part and multiple dose part are started same time.
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
16 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
THR-1442 20mg Single dose group
Arm Type
Experimental
Arm Description
THR-1442 20mg Single dose group: subject will be administrated 1 dose of 20mg THR-1442 on day1, the follow up till day 7.
Arm Title
THR-1442 20mg Multiple dose group
Arm Type
Experimental
Arm Description
THR-1442 20mg Multiple dose group: subject will be administrated THR-1442 20mg QD on Day1-Day7, the follow up till day 14.
Intervention Type
Drug
Intervention Name(s)
THR-1442 20mg Single dose
Intervention Description
THR-1442 20mg is administrated 1 dose on Day 1, then follow till day 7.
Intervention Type
Drug
Intervention Name(s)
THR-1442 20mg Multiple dose group
Intervention Description
THR-1442 20mg is administrated QD for 7days, then follow till day 14.
Primary Outcome Measure Information:
Title
Collect and evaluate TEAEs (including clinical AEs and Lab AEs) of THR-1442 in healthy subjects during study
Description
Collect data(TEAEs including clinical AEs and lab AEs) on Day7 and Day14 to evaluate THR1442 safety and tolerability
Time Frame
Single dose:Baseline to day 7 ; Multiple dose:Baseline to Day14
Secondary Outcome Measure Information:
Title
Select and evaluate pharmacokinetic characteristics(AUC) of THR-1442 in healthy subjects during the study
Description
Collect blood samples on Single dose part and multiple dose part to evaluate THR1442 PK parameters (AUC)
Time Frame
Single dose:Day1-Day7; Multiple dose:Day1- Day14
Title
Select and evaluate pharmacokinetic characteristics(Cmax) of THR-1442 in healthy subjects during the study
Description
Collect blood samples on Single dose part and multiple dose part to evaluate THR1442 PK parameters (Cmax)
Time Frame
Single dose:Day1-Day7; Multiple dose:Day1- Day14
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
45 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Be able to understand and be willing to sign informed consent and voluntarily participate in the study;
Chinese women or men aged 18-45 (including 18 and 45) at the time of screening;
Men or women who agree to effective contraception from the screening period until 30 days after the last dose in the trial; Agree to take at least one effective contraceptive measure;
During screening and baseline, male weight ≥ 50.0kg, female weight ≥ 45.0kg, body mass index (BMI) in the range of 19 ~ 25.0kg/m2 (including 19 and 25.0kg/m2), [BMI = weight (kg) / height 2 (M2)];
Exclusion Criteria:
According to the judgment of the site investigators, including clinical significant medical history in CNS, CV system, respiratory system, blood / hematopoietic system, gastrointestinal system, liver / kidney system,etc;
Subjects with specific allergic history or allergic constitution such as drugs, food and pollen, or allergic to SGLT2 inhibitors or similar drugs;
Alcoholics (drinking 14 units per week, each unit equivalent to 360mL beer or 150mL wine or 45mL alcohol of 40% alcohol), drug or drug dependence subjects; Smokers (smoking > 5 cigarettes per day or the same amount of other tobacco products);
Subjects with a history of bladder dysfunction, such as urinary incontinence, frequent urination or nocturia;
Blood donation within 3 months before screening, including component blood or massive blood loss (≥ 200ml), receiving blood transfusion or using blood products;
Subjects who used prescription drugs, traditional Chinese medicine, over-the-counter drugs (OTC), vitamins, dietary supplements or supplements (e.g. ginseng) within 4 weeks before the first administration;
From 7 days before the first dose to the whole study period, subjects who are unwilling or unable to guarantee to forbid by the following: no smoking, no alcohol, no caffeine containing products (including chocolate, tea, coffee, cola, etc.) and avoid strenuous exercise;
Those who are unwilling or unable to guarantee to forbid pitaya, grapefruit, mango, carambola, fruit juice and spicy food containing the above fruits from 7 days before taking the medicine and the whole test period;
The subject was unable to swallow the study drug or had gastrointestinal diseases leading to absorption disorders;
Subjects who had participated in any drug or medical device clinical trial within 3 months before screening;
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Owen Zhang
Phone
8621-52998027
Email
owen.zhang@newsoara.com
Facility Information:
Facility Name
Hangzhou First People's hospital
City
Hangzhou
State/Province
Zhejiang
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Fei Wang
Email
hzsygcp@163.com
12. IPD Sharing Statement
Learn more about this trial
Safety, Tolerance and Pharmacokinetics of THR-1442 in Chinese Healthy Subjects
We'll reach out to this number within 24 hrs